Sanofi (SNY) has released an update. Sanofi’s Dupixent has shown promising results in a Phase 3 trial for treating chronic spontaneous urticaria, significantly reducing symptoms like itch and ...

Powered by PandaOmics, Insilico’s proprietary generative biology AI platform, the joint R&D team comprising Insilico Medicine and Sanofi colleagues focused on highly novel targets known to be ...

UBS analyst Jo Walton maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €110.00. The company’s shares closed yesterday at $111.91. According to ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

Sanofi (SNY) announced Beyfortus will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration of this immunization to ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €112.00. David Risinger has given his Buy rating due to a ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Sanofi (SNYNF – Research Report), with a price target of €90.00. The company’s shares closed ...

TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead ...

In a report released today, Elmar Kraus from DZ BANK AG maintained a Hold rating on Sanofi (SNYNF – Research Report). The company’s shares closed last Thursday at $102.35. Kraus covers the ...

Opella Valuation: EUR16 billion EV, 14 times 2024 estimated EBITDA. Sanofi SA (NASDAQ:SNY) reported a strong sales performance with Q3 sales reaching EUR13.4 billion, marking a 16% increase in ...